{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:50:36Z","timestamp":1791805836398,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3933,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1111\/j.1523-1755.2005.00178.x","type":"journal-article","created":{"date-parts":[[2005,2,7]],"date-time":"2005-02-07T14:10:13Z","timestamp":1107785413000},"page":"1120-1125","source":"Crossref","is-referenced-by-count":102,"title":["Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients"],"prefix":"10.1016","volume":"67","author":[{"given":"Junichiro J.","family":"Kazama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitake","family":"Gejyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 11","key":"10.1111\/j.1523-1755.2005.00178.x_bb0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ndt\/17.suppl_11.20","article-title":"Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis","volume":"17","author":"Drueke","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","article-title":"Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients","volume":"92","author":"Fukuda","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s002689900113","article-title":"Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism","volume":"20","author":"Tominaga","year":"1996","journal-title":"World J Surg"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1523-1755.2002.kid585.x","article-title":"Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism","volume":"62","author":"Tokumoto","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0272-6386(97)90352-8","article-title":"Are we mismanaging calcium and phosphate metabolism in renal failure?","volume":"29","author":"Hsu","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","article-title":"Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product","volume":"23","author":"Moe","year":"2003","journal-title":"Am J Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000188261","article-title":"Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients","volume":"68","author":"Fukagawa","year":"1994","journal-title":"Nephron"},{"issue":"Suppl 3","key":"10.1111\/j.1523-1755.2005.00178.x_bb0045","first-page":"34","article-title":"Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology","volume":"18","author":"Onoda","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0050","series-title":"Kidney Int","first-page":"155","article-title":"Pathogenesis of refractory secondary hyperparathyroidism","author":"Rodriguez","year":"2002"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","article-title":"Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain","volume":"277","author":"Yamashita","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium","volume":"26","author":"White","year":"2000","journal-title":"Nat Genet"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0065","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0070","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00016.2003","article-title":"FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization","volume":"285","author":"Quarles","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0075","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00041552-200209000-00011","article-title":"New insights into phosphate homeostasis: Fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia","volume":"11","author":"Kumar","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semnephrol.2003.08.016","article-title":"Renal phosphate wasting disorders: Clinical features and pathogenesis","volume":"24","author":"Brame","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0085","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0090","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1074\/jbc.M207872200","article-title":"Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production","volume":"278","author":"Saito","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0095","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1359\/jbmr.2003.18.7.1227","article-title":"Serum FGF23 levels in normal and disordered phosphorus homeostasis","volume":"18","author":"Weber","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0100","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0105","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1523-1755.2004.00604.x","article-title":"FGF-23 in patients with end-stage renal disease on hemodialysis","volume":"65","author":"Imanishi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","article-title":"Possible involvement of circulating fibroblast growth factor-23 (FGF-23) in the development of secondary hyperparathyroidism in predialysis patients","volume":"44","author":"Shigematsu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0115","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0120","first-page":"307","article-title":"Receiver operating characteristic (ROC) methodology: The state of the art","volume":"29","author":"Hanley","year":"1989","journal-title":"Crit Rev Diagn Imaging"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000057599","article-title":"Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases","volume":"91","author":"Kazama","year":"2002","journal-title":"Nephron"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"issue":"Suppl 10","key":"10.1111\/j.1523-1755.2005.00178.x_bb0140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ndt\/17.suppl_10.2","article-title":"Renal osteodystrophy and secondary hyperparathyroidism","volume":"17","author":"Fukagawa","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.semnephrol.2003.08.014","article-title":"Vascular calcification in chronic kidney disease","volume":"24","author":"Chen","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0150","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.ajkd.2003.12.005","article-title":"Vascular Calcification Work Group. Vascular calcification in chronic kidney disease","volume":"43","author":"Goodman","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0155","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1523-1755.2001.060002472.x","article-title":"Pathophysiological mechanisms of vascular calcification in end-stage renal disease","volume":"60","author":"Davies","year":"2001","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0160","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0165","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ndt\/gfh038","article-title":"Intact PTH assay overestimates true 1\u201384 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism","volume":"19","author":"Kazama","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0170","doi-asserted-by":"crossref","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of FGF23 expression but not degradation by Phex","volume":"278","author":"Liu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0175","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0272-6386(04)00817-0","article-title":"Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism","volume":"44","author":"Sato","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0180","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1074\/jbc.M210490200","article-title":"The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency","volume":"278","author":"Bai","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0185","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1523-1755.2005.00178.x_bb0190","doi-asserted-by":"crossref","first-page":"F739","DOI":"10.1152\/ajprenal.00321.2003","article-title":"Differential regulation of PHEX expression in bone and parathyroid gland by chronic renal insufficiency and 1,25-dihydroxyvitamin D3","volume":"286","author":"Brewer","year":"2004","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815505590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815505590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T17:50:06Z","timestamp":1548784206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815505590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0085253815505590"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00178.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}